UNSPSC 51332839: Chlorpromazine hibenzate

This classification denotes a phenothiazine and antipsychotic agent C17H19ClN2S.C14H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 657G38Q829, chemically known as benzoic acid, 2-(4-hydroxybenzoyl)-, compd. with 2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine (1:1), but more generally known as chlorpromazine hibenzate, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine hibenzate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22077.

Most nations, for tariff and trade purposes, schedule chlorpromazine hibenzate under HS 29343090 and SITC 51578. As of Q4 2014, CHLORPROMAZINE HIBENZATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CC(CC3)CL.C1CCC(C(C1)C(=O)C2CCC(CC2)O)C(=O)O.

UNSPSC 51332839 Chlorpromazine hibenzate is a Commodity code nominally for a specific pharmaceutical product, but recent state and local solicitation activity tagged to this code shows little alignment with chlorpromazine itself. The actual procurement activity under this code spans naloxone acquisition for emergency response, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing. State and local issuing bodies posting opportunities under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work reflects broader pharmaceutical procurement — emergency medications, pharmacy benefit program administration, and generic drug supply through authorized wholesalers — rather than a single active pharmaceutical ingredient.

Activity appears in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, marking an exploratory phase before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline, requiring vendors to supply through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The mismatch between the code's nominal scope and the actual solicitations posted suggests this code may be applied inconsistently or serves as a catchall for pharmaceutical procurement activity at the state and local level.